PLUS1
31.25
-0.41 (-1.3%)
-0.41 (-1.3%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Denali Therapeutics Inc | DNLI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.41 | -1.3% | 31.25 | 31.21 | 34.8777 | 32.5746 | 31.66 | 11:59:06 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 31.21 | 31.32 | 0.11 | 0.35% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,290 | 870,575 | $ 33.01 | $ 28,734,664 | 571,049 | 12.39 - 35.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:59:06 | 100 | $ 31.25 | USD |
Denali Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.50B | 105.63M | 59.61M | $ 26.68M | $ - | -2.07 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Denali Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/06/2020 | 09:17 | Dow Jones News | Biogen to Buy Stake in Denali for $465 Million as Part of.. |
| 8/06/2020 | 08:52 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/06/2020 | 08:07 | GlobeNewswire Inc. | Denali Therapeutics Announces Decision to Advance DNL151.. |
| 8/06/2020 | 08:02 | GlobeNewswire Inc. | Biogen and Denali to Collaborate on LRRK2 Program for.. |
| 7/29/2020 | 09:00 | GlobeNewswire Inc. | Denali Therapeutics Announces Phase 1b Study by Partner.. |
| 7/07/2020 | 08:00 | PR Newswire (US) | Flagship Pioneering's Scientists Invent a New Category of.. |
| 6/30/2020 | 19:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DNLI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 24.12 | 35.70 | 22.75 | 30.15 | 1,548,641 | 7.13 | 29.56% |
| 1 Month | 26.97 | 35.70 | 22.36 | 27.77 | 690,545 | 4.28 | 15.87% |
| 3 Months | 22.94 | 35.70 | 21.41 | 26.36 | 614,277 | 8.31 | 36.22% |
| 6 Months | 25.33 | 35.70 | 12.39 | 23.16 | 565,383 | 5.92 | 23.37% |
| 1 Year | 18.46 | 35.70 | 12.39 | 21.69 | 495,298 | 12.79 | 69.28% |
| 3 Years | 21.55 | 35.70 | 12.32 | 20.56 | 428,081 | 9.70 | 45.01% |
| 5 Years | 21.55 | 35.70 | 12.32 | 20.56 | 428,081 | 9.70 | 45.01% |
Denali Therapeutics Description
| Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle) and others. |
